So much about IVDR is unprecedented. It relegates re-classification to a small minority, and it completely overhauls the expectations associated with your pre-market and post-market data.

This means that capturing the right data and preparing the right documentation for IVD development is going to be more important — and more difficult — than ever. As such, staying on time and on budget will require expert insight with the answers to the most important questions surrounding the IVDR transition:

  • Where does my IVD device belong under new risk classifications?
  • What all is contained within a high-quality performance evaluation plan (PEP)?
  • How has post-market surveillance (PMS) evolved and what is now required?

Successful development will be possible only for those MedTech organizations who can incorporate these new considerations into existing pre-market and post-market procedures for their in vitro medical devices. Read our white paper on “understanding IVDR” to start your organization on a successful regulatory transition.

Download White Paper

Back to Resources

Your product is important, and your trial deserves the team that has what it takes. It takes knowledge. It takes passion. It takes commitment. It Takes Avania.

Let’s Talk